Yuli 2022: Dabrafenib (Tafinlar, Novartis) da trametinib (Mekinist, Novartis) sun sami karɓuwa mai ƙarfi daga Hukumar Abinci da Magunguna don kula da manya da marasa lafiyar yara waɗanda suka girmi shekaru 6 da rashin lafiya.
Yuni 2022: Bayan layi biyu ko fiye na tsarin jiyya, FDA ta ba da lambar yabo ta tisagenlecleucel (Kymriah, Novartis Pharmaceuticals Corporation) da gaggawar yarda ga manya marasa lafiya tare da relapsed ko refractory follicular lymphoma (FL).T.
Afrilu 2022: Hukumar Abinci da Magunguna ta amince da Pluvicto (lutetium Lu 177 vipivotide tetraxetan, Advanced Accelerator Applications USA, Inc., kamfanin Novartis) don kula da manya marasa lafiya tare da takamaiman mem na prostate.
Maris 2022: Hanyar juyin juya hali ga CAR-T Cell far yana da yuwuwar juyar da abin da ya zama axiom na likita: cewa babban tasirin maganin akan ciwace-ciwacen daji ya zo ne a cikin kashe manyan hatsari ga mai haƙuri.
Immunotherapy a maganin ciwon dajiCancer CAR-NK far yana da tasiri mai tasiri na 73%, kuma ana daukar shi a cikin gwaje-gwajen asibiti na gida.Immunotherapy ya canza yadda ake magance ciwon daji. Ciwon daji immunotherapy yana rarraba..